Prof. Dr. Konstanze Döhner - The Practicalities of Personalised Therapy in AML: The Who, How, When, and Why of Treating IDH1-Mutated Disease

Karen C. Daily, D.O. - RiskReady: A Systems Approach to Improving the Recognition and Treatment of High-Risk, HR+, HER2- Early Breast Cancer

Lynsey P. Teulings, APRN - Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease

Susana Banerjee, MBBS, MA, FRCP, PhD, Ana Oaknin, MD, PhD - Putting the Puzzle Together in Advanced Ovarian and Cervical Cancers: Translating Evidence Into Practice for Approved and Emerging ADCs

Professor Stephen Johnston, MA, FRCP, PhD - Charting New Paths in the Treatment of ER+, HER2- MBC: Seeking Clarity and Consensus Through Evidence-Aligned Clinical Cases

Erica L. Mayer, MD, MPH - Nurturing Lasting Benefits of Adjuvant CDK4/6 Inhibitor Therapy in High-Risk HR+, HER2- EBC: Best Practices for Patient Education, AE Monitoring and Management, and Enhanced Adherence/Persistence

Angela Lamarca, MD, PhD, MSc - The Power of Personalised Approaches in Advanced CCA: Team-Based Strategies to Individualise Clinical Care

Susana Banerjee, MBBS, MA, FRCP, PhD, Kathleen N. Moore, MD, MS - Harnessing the Power of ADCs in Gynecologic Cancers: Expert Insights for Practice Integration

Erica L. Mayer, MD, MPH - Risk Assessment and Treatment Initiation: Successfully Jumpstarting the Adjuvant CDK4/6 Inhibitor Treatment Journey in HR+, HER2- EBC

Yelena Y. Janjigian, MD*, Siva Raja, MD, PhD, FACS - Critical Conversations for Surgeons and Oncologists in Resectable Gastric/GEJ Cancer: Expert Guidance on Integrating Rapidly Evolving Evidence for Immunotherapy Platforms

Prof. Nicolas Girard, MD, PhD / Pasi A. Jänne, MD, PhD - Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents

Nikhil I. Khushalani, MD - The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable Disease

Prof. Sanjay Popat, FRCP, PhD - The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC

Paolo Ghia, MD, PhD - The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi Combinations

Julie R. Brahmer, MD, MSc, FASCO - Maximizing the Potential and Expanding the Impact of Immunotherapy in Advanced NSCLC

Komal Jhaveri, MD, FACP - Visual Exploration of the Evolving Role of Novel Oral SERDs, Other ER-Targeting Therapies, and Rational Combinations in ER+, HER2- MBC

Nitin Jain, MD - Committing to Advances for CLL Care: Conversations on Modern Standards of Care and Next-Gen Innovation

Komal Jhaveri, MD, FACP - Changing the Scenery in ER+, HER2- MBC With New Oral SERDs and Combinations: Foundations, Evidence, and Practicalities

Haley A. Moss, MD, MBA / Angeles Alvarez Secord, MD, MHSc - Implementing Immuno-Oncology in Gynecologic Cancer Care for Veterans: Expert Insights on Personalized Treatment

Krish Patel, MD - Mapping Therapeutic Directions in DLBCL: Team Strategies for Prognostic Assessment and Implications for Targeted Therapy and Other Innovative Options